Ambiguities in identifying phenotypes may be the rate-limiting step in psychiatric genetic studies
+(1). Consequently, new strategies are being tested to identify elemental components of the phenotype more closely related to susceptibility alleles than are complex clinical phenotypes, such as schizophrenia or bipolar disorders. These intermediate phenotypes might have a simple genetic architecture, and if so, they could be used to enhance the power of linkage and association studies of complex disorders. Intermediate phenotypes may also help solve the problem of the threshold definition of spectrum disorders found either in relatives of schizophrenia probands (i.e., with schizophreniform disorder, schizoaffective disorder, and schizotypal personality disorder) or in relatives of bipolar probands (i.e., with unipolar depression, major depressive episodes, cyclothymic and hyperthymic temperaments). In recent years, improved diagnostic tools have stimulated the search for quantitative phenotypes among patients and relatives. In particular, negative symptoms that represent deficiencies in normal behavior (such as flat affect and social withdrawal) and positive symptoms that represent behavioral excesses (e.g., delusions and hallucinations) have emerged as likely candidates for family studies mostly in schizophrenia but also in affective disorders. The Scale for the Assessment of Negative Symptoms (SANS) and the Scale for the Assessment of Positive Symptoms (SAPS) are commonly used to rate these symptoms
+(2). Negative symptoms appear to be more stable over time than positive symptoms
+(3) and seem to be the main source of familial aggregation in schizophrenia. Negative symptoms have been shown to be correlated between pairs concordant for schizophrenia
+(4), and they appear to be correlated with a positive family history of schizophrenia
+(5,
+6). More precisely, we have demonstrated the existence of a subform of schizophrenia characterized by highly anhedonic schizophrenia probands with both a three times higher familial risk for schizophrenia spectrum disorders and a high level of anhedonia among their first-degree relatives
+(6). Using the SAPS and the SANS, Tsuang
+(1) showed that negative symptoms ratings are higher for the relatives of schizophrenia probands, whereas positive symptoms were similar among the relatives of schizophrenia patients and depressive control subjects. These findings suggest that negative symptoms could reflect familial liability to schizophrenia, whereas positive symptoms could reflect a clinical endophenotype common both to affective disorders and to schizophrenia. Indeed, family studies suggest shared liability between schizophrenia and affective disorders. Three data sets
+(7–
+9) have shown a higher than comparison rate of psychotic affective disorders in the relatives of schizophrenia probands, and Potash et al.
+(10) showed a familial aggregation of psychotic symptoms in affected relatives of bipolar I patients. Genetic linkage studies have also revealed an overlap between bipolar disorders and schizophrenia in four chromosomal regions (10p12–13, 13q32, 18p11.2, 22q11–13)
+(11). Thus, there may be a shared phenotype common to bipolar disorder and schizophrenia, and this common phenotype may be part of a positive symptom profile. Brzustowicz et al.
+(12) provided the first evidence of the value of using positive symptoms in linkage studies in multiplex schizophrenia families. Positive linkage with chromosome 6p markers was obtained only when using scores for positive symptoms as the phenotype among both schizophrenia patients and their nonaffected relatives, while negative linkage results were obtained with negative symptom scores or with a classical nosographical approach.